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Abstract
Genes in the Leukocyte Antigen 6 (Ly-6) superfamily encode glycosyl-phosphatidylinositol (GPI)
anchored glycoproteins (gp) with conserved domains of 70 to 100 amino acids and 8 to 10 cysteine
residues. Murine Ly-6 genes encode important lymphocyte and hematopoietic stem cell antigens.
Recently, a new member of the human Ly-6 gene superfamily has been described, CD177. CD177 is
polymorphic and has at least two alleles, PRV-1 and NB1. CD177 was first described as PRV-1, a gene
that is overexpressed in neutrophils from approximately 95% of patients with polycythemia vera
and from about half of patients with essential thrombocythemia. CD177 encodes NB1 gp, a 58–64
kD GPI gp that is expressed by neutrophils and neutrophil precursors. NB1 gp carries Human
Neutrophil Antigen (HNA)-2a. Investigators working to identify the gene encoding NB1 gp called
the CD177 allele they described NB1. NB1 gp is unusual in that neutrophils from some healthy
people lack the NB1 gp completely and in most people NB1 gp is expressed by a subpopulation of
neutrophils. The function of NB1 gp and the role of CD177 in the pathogenesis and clinical course
of polycythemia vera and essential thrombocythemia are not yet known. However, measuring
neutrophil  CD177  mRNA levels has become an important marker for diagnosing the
myeloproliferative disorders polycythemia vera and essential thrombocythemia.
Introduction
CD177 is an important neutrophil gene that encodes the
neutrophil membrane glycoprotein (gp) NB1. NB1 gp has
been studied for more than 20 years and during that time
several different names have been used to describe this gp,
its antigens, and the gene that encodes this molecule. NB1
was first described by Lalezari and colleagues while inves-
tigating a case of neonatal alloimmune neutropenia [1].
Occasionally, during pregnancy, a mother produces
alloantibodies to neutrophil antigens than cross the pla-
centa, react with neutrophils in the fetus, and cause the
neonate to become neutropenic. One antigen recognized
by such antibodies was described as "NB1" by Lalezari in
1971 [1]. Later, this antigen was renamed as Human Neu-
trophil Antigen-2a (HNA-2a) and the gp carrying this
antigen was called NB1 gp [2]. Monoclonal antibodies
specific for NB1 gp have been produced and clustered as
CD177 [3]. In 2001 Kissel and colleagues sequenced the
gene encoding NB1 gp and called the gene NB1 [4]. How-
ever, this gene was highly homologous to a gene called
PRV-1 that had been sequenced the year before. Temeri-
nac and colleagues identified and sequenced PRV-1  in
2000 while searching for genes overexpressed in neu-
trophils from patients with polycythemia vera [5]. The
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coding regions of NB1 and PRV-1 differ at only 4 nucle-
otides that result in amino acid changes and Caruccio,
Bettinotti, and colleagues have shown that PRV-1  and
NB1 are alleles of a single gene which in this review is
referred to as CD177 [6-8] (Table 1).
CD177, NB1 glycoprotein, and neutrophils from 
healthy subjects
NB1 glycoprotein
NB1 gp has been studied for many years since it carries the
neutrophil alloantigen HNA-2a. Investigations with
alloantibodies and monoclonal antibodies revealed that
NB1 gp has a mass of 58 to 64 kD on analysis by SDS-
PAGE and 50.5 kDa as determined by MALDI-TOF mass
spectrometry [4] (Table 1). It is a glycosyl-phosphatidyli-
nositol (GPI) anchored gp that is found on neutrophil
plasma membranes and secondary granules [9,10]. NB1
gp containes N-linked carbohydrate side chains but not
O-linked carbohydrates. NB1 gp is a neutrophil-specific
protein in that it is expressed by neutrophils, neutrophilic
metamyelocytes, and myelocytes, but not by any other
blood cells [11].
Structure of CD177
CD177 belongs to the Leukocyte Antigen 6 (Ly-6) super-
gene family and is located on chromosome 19q13.2 [4-6].
It has 9 exons and an open reading frame of 1311 bp and
encodes 437 amino acids with an N-terminal signal
sequence of 21 amino acids [4-6]. The predicted structure
of the encoded protein is consistent with NB1 gp. The pre-
dicted protein has 3 N-glycosylation sites and a hydro-
phobic C terminus with a GPI attachment (ω). The
predicted molecular mass of the protein is 44.2 kDa [4].
The predicted protein has two highly homologous
cysteine-rich domains of 188 amino acids. Each domain
has 6 cysteine residues. Immediately adjacent to CD177 is
a pseudogene that is highly homologous to exons 4
through 9 of CD177 in tail to head orientation [6].
Heterogenous neutrophil expression of NB1 gp
NB1 gp is unusual in that it is expressed on subpopula-
tions of neutrophils. The mean size of the NB1 gp-positive
subpopulation of neutrophils is 45% to 65% [12,13] and
it ranges from 0% to 100%. Estrogen and possibly proges-
terone seem to affect the expression of NB1 gp. The
expression of NB1 gp is greater on neutrophils from
women than men [13]. The size of the NB1 gp-positive
subpopulation of neutrophils from women is approxi-
mately 49% to 59% compared to approximately 42% to
43% for men. The expression of NB1 gp falls with age in
women, but remains constant in men [13]. Neutrophil
expression of NB1 gp is even greater in pregnant women
than in healthy female blood donors. Approximately 67%
to 70% of neutrophils from pregnant women express NB1
gp [14]. Interestingly, neutrophil counts are also greater
during pregnancy. The administration of G-CSF to healthy
subjects for several days increases the proportion of neu-
trophils expressing NB1 gp to nearly 90% by an unknown
mechanism [15].
The absence of NB1 gp expression by subpopulations of
neutrophils is due to the lack of CD177 mRNA transcrip-
tion. A comparison of CD177 mRNA between NB1 gp
expressing and non-expressing neutrophils from the same
people revealed that CD177 mRNA was absent from neu-
trophils that did not express NB1 gp [16]. In addition, one
day after the administration of 5 µg/kg of body weight of
G-CSF to healthy subjects the size of the NB1 gp positive
neutrophil population did not change and CD177 mRNA
remained absent from NB1 gp negative neutrophils,
however CD177 mRNA levels increased 1000-fold in NB1
gp expressing neutrophils.
NB1 gp deficient neutrophils
NB1 gp is absent from all neutrophils in some healthy
people. Analysis of neutrophils from these NB1 gp defi-
cient people with several different monoclonal and
alloantibodies specific to NB1 gp have found that their
membranes lack the entire NB1 gp. Approximately 3% of
Caucasians, 5% of African Americans, and 1% to 11% of
Japanese have NB1 gp deficient neutrophils [13,17,18].
One of the causes of NB1 gp deficient neutrophil pheno-
type is a CD177 mRNA splicing defect [19]. CD177 mRNA
was analyzed from two NB1 gp deficient people, and
although CD177 mRNA was present in both, frame shift
mutations in CD177 mRNA were detected [19]. Insertions
of intron sequences that created stop codons were found.
The deduced protein in both people lacked transmem-
brane segments and GPI linkage sites. No NB1 gp or pro-
Table 1: Characteristics of CD177 and the NB1 glycoprotein it 
encodes
CD177
Location 19q13.2
Alleles PRV-1, NB1
Expressed by Neutrophils
Homologous genes uPAR (CD87), CD59
NB1 gp
Mass 58 to 64 kDa
Number of amino acids 416
Protein type Gycosylinositol anchored
Glycosylation N-linked side chains
Neutrophil location Plasma membranes and 
secondary granules
Epitope HNA-2aJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/8
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tein fragments were detected on neutrophils or in their
plasma [19]. People with NB1 gp deficient neutrophils are
healthy, but too few have been studied to determine if the
absence of this protein has a subtle effect on neutrophil
counts, neutrophil function, host defense, or host
response to inflammation.
The expression of NB1 gp is also absent from neutrophils
from people with paroxysmal nocturnal hemoglobinuria
(PNH) and in many people with CML [10,11]. NB1 gp is
absent on neutrophils from people with PNH since it is a
GPI-anchored protein and GPI anchored proteins are
absent from blood cells of people with PNH. It is not
known why some patients with CML do not express NB1
gp. It is not known if the lack of expression of NB1 gp on
neutrophils from patients with PNH or CML has any clin-
ical significance.
CD177 polymorphisms
Several polymorphisms of CD177 have been described.
The most common allele of CD177  is the allele that
Temerniac et al described as PRV-1 [5]. Kissel and col-
leagues described a second allele, NB1 [4]. The PRV-1 and
NB1 alleles differ at only 4 bp that result in amino acid
changes [4]. These single nucleotide polymorphisms are a
G to C change of bp 42, a C to T change at bp 390, a G to
A change at bp 1003, and a T to C change at 1171. Initially
it was not appreciated that PRV-1 and NB1 were alleles of
the same gene. Bettinotti and colleagues used Human
Genomic Project databases to characterize the structure of
the PRV-1 and NB1 genes [6]. They described the intron
and exon structure of PRV-1, but they found only one
gene homologous to both PRV-1 and NB1 suggesting that
they are alleles of the same gene that is now called CD177.
In addition, they found a pseudogene homologous to
exons 4 through 9 of CD177 [6].
The most common polymorphism in CD177 is a single
nucleotide G to C change at bp 42 that results in an amino
acid substitution in the protein signal sequence. This pol-
ymorphism is present in approximately 40% of healthy
subjects [7]. It appears that this polymorphism is associ-
ated with an increase in size of the neutrophil population
that expresses NB1 gp. Caruccio and colleagues found that
the size of the NB1 gp expressing neutrophil population
in 42 G homozygous individuals was 41% compared to
66% in 42 C homozygous individuals [7]. They also iden-
tified additional single nucleotide polymorphisms (SNPs)
predicted to result in amino acid substitutions including
A to T at bp 123, G to A at bp 145, G to A at bp 1077 and
A to T at bp 1099 [7]. However, since these SNPs were
present in only about 10% of subjects it could not be
determined if they affected NB1 gp expression. Wolff and
colleagues also found that G42C was associated with the
size of the neutrophil population expressing NB1 gp [16].
In addition, they found that SNPs at 786 and 1077 were
associated with changes in the size of the neutrophil pop-
ulation expressing NB1 gp. Wolff and colleagues
sequenced the CD177 promoter region from the begin-
ning of exon 1 and prior to 162 bp upstream, but no pol-
ymorphisms were found [16]. While SNPs likely
contribute to the variable expression of NB1 gp, other
mechanisms that have not yet been identified are also
likely involved with the heterogenous expression of NB1
gp.
Increased neutrophil CD177 mRNA levels in infection and 
inflammation
Increases in neutrophil CD177 mRNA levels are seen in
clinical conditions associated with increased neutrophil
production such as people with severe infections or burns
and in healthy subjects given G-CSF [16,20]. In patients
given 10 µg/kg of G-CSF twice daily over 4 days CD177
mRNA levels increased markedly [5]. Neutrophil CD177
mRNA levels are not increased in patients with chronic
myelogenous leukemia or acute myelogenous leukemia
[5].
Function of CD177
People with a NB1 gp null phenotype are healthy and the
function of their neutrophils is normal. These results sug-
gest the function of NB1 gp may be duplicated by another
protein. One study suggests that NB1 gp has a role in the
adhesion of neutrophils to endothelial cells [21]. The neu-
trophil protein that is most similar in structure to NB1 gp
is urokinase type plasminogen activator receptor (uPAR or
CD87). uPAR has a number of roles in cell function. Inter-
estingly, it is involved in leukocyte adhesion and
adhesion to marrow stroma [22]. It is not known if NB1
gp affects adhesion to marrow stroma.
CD177 and polycythemia vera
Polycythemia vera
Polycythemia vera is a myeloproliferative disorder. In
addition to polycythemia vera, traditional classifications
of myeloproliferative disorders include essential throm-
bocythemia, chronic myelogenous leukemia (CML), and
idiopathic myelofibrosis. All four disorders are clonal
hematopoietic progenitor disorders involving erythropoi-
esis, myelopoiesis, and thromobpoiesis. The predomi-
nant characteristic of polycythemia vera is the
overproduction of red blood cells. Essential thrombo-
cythemia is characterized best by the overproduction of
platelets. In CML granulocytes are overproduced. In idio-
pathic myelofibrosis marked fibrosis of the bone marrow
is present. The molecular abnormalities in CML are well
characterized. CML is characterized by the Philadelphia
chromosome which is due to a reciprocal translocation
between chromosomes 9 and 22, t(9;22)(q34;q11.2). InJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/8
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contrast, until recently little was known of the molecular
basis of the other myeloproliferative disorders [23-25].
The incidence of polycythemia vera in North America is
approximately 2 per 100,000. Polycythemia vera is most
common in patients greater than 40 years of age and the
median age at diagnosis is 60 years. Polycythemia vera is
slightly more common in men than women [25]. The pre-
dominant clinical feature of polycythemia vera is the over-
production of red blood cells and increased red blood cell
mass. Other clinical features of polycythemia vera include
increased platelet counts, increased neutrophil counts and
splenomegaly. Neutrophil counts are not, however,
increased to the same degree as the red cell mass and
platelet counts.
The growth of hematopoietic progenitors from patients
with polycythemia vera is abnormal. In healthy subjects
the growth of erythroid colonies from the blood or bone
marrow requires the addition of growth factors including
erythropoietin. Erthyroid colonies from patients with
polycythemia vera are hypersentive to erythropoietin and
a number of other hematopoietic growth factors. Eryth-
roid colonies from patients with polycythemia vera form
in culture in the absence of the addition of exogenous
erythropoietin. These seemingly growth factor independ-
ent colonies are known as erythropoietin independent
erythroid colonies.
Polycythemia vera and neutrophil overexpression of 
CD177
Several chromosomal abnormalities have been described
in patients with polycythemia vera, but most are found in
30% or less of patients. No one chromosomal abnormal-
ity has been found in all patients, but recently a molecular
abnormality has been found in nearly all patients with
polycythemia vera. Several studies have found that 95% to
100% of patients with polycythemia vera have markedly
elevated levels of neutrophil CD177  mRNA [5,26-30].
Temerinac and colleagues compared genes expressed by
neutrophils from patients with polycythemia vera with
those expressed by neutrophils from healthy subjects [5].
They used subtractive hydridization to clone complemen-
tary DNA (cDNA) of genes that were overexpressed or
underexpressed by neutrophils from patients with poly-
cythemia vera in comparison to healthy individuals. They
found that only one gene was strongly overexpressed in
the polycythemia neutrophils, CD177. They tested 19
patients with polycythemia vera and found high numbers
of neutrophil CD177  mRNA in all 19, but neutrophil
CD177 mRNA was nearly absent from neutrophils from
all 21 healthy subjects tested. Temerinac also studied neu-
trophils from a small number of patients with essential
thrombocythemia and idiopathic myelofibrosis and some
were also found to have increased neutrophil CD177
mRNA levels [5].
Several other studies have confirmed the overexpression
of neutrophil CD177 mRNA in polycythemia vera, and
two other myleoproliferative disorders, essential throm-
bocythemia and idiopathic myelofibrosis [5,26-31]
(Table 2). The number of patients expressing increased
quantities of CD177 mRNA varies among the disease type
and among studies. The proportion of patients with ele-
vated CD177 mRNA levels is greatest in those with poly-
cythemia vera and least in those with idiopathic
myelofibrosis. Elevated CD177 mRNA levels have been
found in 90% to 100% of patients with polycythemia
vera, 30% to 50% of patients with essential thrombo-
cythemia, and 10% to 30% of patients with idiopathic
myelofibrosis. Patients with essential thrombocythemia
and increased levels of neutrophil CD177 mRNA are at
increased risk of thromboembolic  and major bleeding
complications compared to essential thrombocythemia
patients with normal CD177 mRNA levels [32]. It is not
known if increased expression of CD177 mRNA levels are
directly responsible for the increased risk of vascular com-
plications or if increased CD177 mRNA levels are simply
a marker of a subset of patients with more severe disease.
Some of the differences in the proportion of polycythemia
vera patients with elevated CD177 mRNA levels may be
due to variations in treatment. The treatment of poly-
cythemia vera by phlebotomy or hydroxyurea has no
effect on neutrophil CD177  mRNA levels, however,
CD177 mRNA levels are reduced by interferon-α treat-
ment. Fruehauf and colleagues monitored four patients
with polycythemia vera who had elevated CD177 mRNA
Table 2: Proportion of patients with myeloproliferative disorders who have elevated neutrophil CD177 mRNA levels
Disorder Increased with CD177 levels (%) References
Polycythemia vera 95%, 69%, 91%, 100% [5,26,29,31]
Essential thromobocythemia 21%, 100%, 17%, 67%, 33% [5,26,29-31]
Idiopathic myelofibrosis 67% [26]
Chronic myelogenous leukemia 0% [5]Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/8
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levels during interon-α treatment and found that CD177
mRNA levels fell to normal within six months in all four
patients [28].
Patients with secondary erythrocytosis have increased
hemoglobin levels but they do not have hematopoietic
stem cell abnormalities. Neutrophils from patients with
secondary erythrocytosis do not have increased levels of
neutrophil CD177 mRNA [5,27]. As a result the measure-
ment of CD177 mRNA levels has become a useful diag-
nostic tool for distinguishing polycythemia vera from
secondary erythrocytosis.
While CD177 is almost universally overexpressed in poly-
cythemia vera, the mechanisms of overexpression are not
known. No abnormalities in CD177 have been found in
polycythemia vera. Analysis of the structure of CD177 in
patients with polycythemia vera by Southern blotting and
fluorescence in situ hybridization (FISH) did not reveal
any abnormalities in the CD177 gene. FISH analysis of
CD177 from bone marrow cells from 26 patients with
polycythemia vera did not reveal any deletions, transloca-
tions, or insertions of CD177  [33]. Southern blotting
analysis of neutrophil DNA from eight patients with poly-
cythemia vera did not reveal any gross abnormalities [34].
It is not known if single nucleotide polymorphisms
(SNPs) in CD177  are more common in patients with
polycythemia vera.
NB1 glycoprotein expression in polycythemia vera
NB1 gp is the neutrophil protein encoded by CD177.
Although the expression of CD177 mRNA is markedly ele-
vated in neutrophils from patients with polycythemia
vera, the quality of NB1 gp expressed by neutrophils from
polycythemia vera patients is similar to healthy subjects
[34].
Ly6/uPAR gene family
The Ly-6 gene superfamily is also known as the uPAR or
snake toxin family. This superfamily is characterized by
conserved cysteine rich domains. Typically these domains
contain 70 to 100 amino acids including eigth to ten
cysteine residues spaced at conserved distances. The Ly-6
superfamily includes two subfamilies. One subfamily
encodes GPI-anchored glycoproteins and the other sub-
family encodes secretory proteins without a GPI anchor.
In general, the GPI-anchored Ly-6 proteins have domains
with ten cysteines and the secretory proteins have eight.
The protein encoded by CD177, NB1 gp is an exception in
that it is GPI anchored, but it has only six cysteine residues
in its cysteine rich domains. Most Ly-6 proteins have one
cysteine rich domain. Two exceptions are uPAR which has
three cysteine rich domains and NB1 gp which has two
[22]. Members of this family tend to have little homology.
At most, 20% to 30% of amino acids are conserved among
members. The functions of these proteins are diverse, but
not well understood.
Ly-6 genes were first described in mice. They were found
to be expressed by subpopulations of murine lymphoid
and myeloid cells and are now widely used as markers of
murine T cell differentiation and hematopoietic stem cells
[35-38]. Ly-6A/E (Stem cell antigen 1 or Sca-1) is used as
a marker of hematopoietic precursor cells. All murine
hematopietic stem cells express Sca-1. In addition, Sca-1
may be important in murine T cell activation. Ly-6B is a
marker of immature thymocytes and myeloid cells and
may play a role in T cell costimulation. Ly-6C is a marker
of peripheral blood T cell activation. Although the exact
functions of these molecules are not known, they likely
play roles in signal transduction and cell adhesion.
Several Ly-6 superfamily genes in addition to CD177 have
been found in humans (Table 3). Human Ly-6 genes that
encode GPI-anchored proteins with a single cysteine rich
domain include CD59, Sperm Acrosomal Membrane-
Associated Protein 14 (SAMP14), prostate stem cell anti-
gen (PSCA), RIG-E, GML, LYGH, E-48, LY-6K, Secreted Ly-
6/uPAR-Related Protein 1 (SLUPR-1), SLUPR-2 and SP-10.
Two human LY6 genes are secreted proteins, SLURP-1 and
SLURP-2. CD177 is most similar to uPAR, but these two
proteins are only 23% homologous. Most Ly-6 genes are
found in one of three regions of the human genome:
19q13.3, 8q24, and 6p21.3.
Among the LY-6 genes found in humans, CD59 and uPAR
are best described. CD59 or membrane inhibitor of reac-
tive lysis is an important red blood cell membrane mole-
cule that inhibits complement mediated hemolysis. It
inhibits the terminal step of complement activation cas-
cade by preventing the binding of C9 to C5b-8. As a result
CD59 prevents the formation of the polymeric membrane
attack complex (MAC) and protects cells from MAC
induced lysis. CD59 is expressed by erythrocytes and leu-
kocytes. CD59 is an 18-kDa GPI-anchored cell membrane
glycoprotein [39]. CD59 gene has been localized to chro-
mosome 11p13 [40].
uPAR is a high affinity receptor for urokinase-type plas-
minogen activator (uPA). uPAR  is located on chromo-
some 19q13.3 near CD177. The uPAR gene encodes 335
amino acids including a signal sequence of 33 amino
acids [22]. It is an approximately 55 kDa GPI-anchored
membrane glycoprotein and its protein backbone is
approximately 35 kDa. uPAR is expressed by neutrophils,
monocytes and their precursors. Antibodies specific for
uPAR cluster as CD87.
uPAR is an important activator of the proteolytic enzyme
plasmin [22]. When uPAR binds pro-uPA trace amountsJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/8
Page 6 of 9
(page number not for citation purposes)
of plasmin convert pro-uPA to uPA. The membrane asso-
ciated uPA bound to uPAR then converts large quantities
of plaminogen to plasmin, a proteolytic enzyme with
degrades fibrin.
uPAR effects cell function in several ways. It plays a role in
cell-cell and cell-extracelluar matrix adhesion [22]. uPAR
affects cell adhesion by binding the extracellular matrix
molecule vitronectin or cell membrane adhesion mole-
cules β1 and β2 integrins. uPAR plays a role in cell migra-
tion. In migrating monocytes and neutrophils, membrane
bound uPAR is redistributed to the cell's leading edge.
Antibodies to uPAR inhibit monocyte and neutrophil
chemotaxis. uPAR may play an indirect role in myelopoi-
esis by activating uPA and plasmin which may release or
activate cytokines or cytokine precursors sequestered in
the extracellular matrix or bound to cell membranes [22].
SAMP14 is a Ly-6 gene that is expressed only in testis [41].
It has been localized to the outer and inner acrosomal
membranes and acrosome maxtrix of sperm. SAMP14
may have a role in sperm-egg interactions. The gene is
located on chromosome 19q13.33 and the protein is pre-
dicted to have a cysteine rich domain, be GPI-anchored
and about 14 kDa.
PSCA is expressed by normal prostate tissue and its expres-
sion is localized to basal cell epithelium in an area that
contains the stem cell compartment of the prostate
[42,43]. PSCA is upregulated in prostate cancer. It encodes
a GPI-anchored cell surface protein of 123 amino acids
and has four N-glycosylation sites [43]. PSCA is located on
chromosome 8q24.2.
RIG-E was first described as a gene expressed by all-trans-
retinoic acid differentiated acute promyelocytic leukemia
and HLA-60 cell lines [44]. It is also highly expressed by
ovary and malignant thymocytes in T-acute lymphoblastic
leukemia and at lower levels by liver, spleen, lung, uterus,
fetal brain, and fetal thymus. RIG-E is located on chromo-
some 8q24 and encodes a protein with 131 amino acids
of which 20 amino acids are a signal peptide sequence.
RIG-E is GPI anchored [44].
GML expression is induced by tumor suppressor gene p53
[45].  GML  is located on chromosome 8q24.3 and it
encodes a GPI-anchored protein.
LYGH  is expressed by brain and acute lymphoblastic
leukemia cells [46]. It also has a single cysteine rich
domain and a GPI-anchor and is located on chromosome
8q24.3.
Table 3: Human genes belonging to Leukocyte Antigen 6 (Ly-6) gene super family
Gene Cellular expression # Cysteine 
domains
Type of protein Comments Location
CD59 Erythrocytes 1 GPI-anchored Protects cells from membrane attack complex 
induced lysis
11p13
PSCA Prostate 1 GPI-anchored Marker of prostate cancer and increase prostate 
cell division
8q24.2
SLURP-1 (ARS B) 1 Secreted Mutations are associated with Mal de Meleda 
syndrome
8q24.3
SLURP-2 1 Secreted Increased expression in skin keratinocytes in 
psoriasis vulgaris
8q24.3
E-48 (LY6D) Keratinocytes 1 GPI-anchored Overexpressed in head-and-neck squamous cell 
carcinoma
8q24.3
RIG-E Acute promyelocytic 
leukemia cells
1 GPI-anchored Expression is induced by all-trans-retinoic acid 8q24.3
LY6H Brain and acute 
lymphoblastic leukemia
1 GPI-anchored 8q24.3
LYGK Keratinocytes 1 GPI-anchored Overexpressed in head-and-neck squamous cell 
carcinoma
GML 1 GPI-anchored Expression is induced by suppressor gene p53 8q24.3
SP-10 Sperm and testis 1 GPI-anchored Abnormal RNA splicing is common 11q23-q24
SAMP14 Spermatozoan 1 GPI-anchored 19q13.33
CD177 Neutrophil 2 GPI-anchored Increased expression in polycythemia vera 19q13.2
uPAR Neutrophils and monocytes 3 GPI-anchored A high affinity receptor for urokinase type 
plasminogen activator
19q13.3
PSCA = Prostate Stem Cell Antigen SLURP-1 = Secreted Ly-6/uPAR Related Protein 1 SLURP-2 = Secreted Ly-6/uPAR Related Protein 2 SAMP14 = 
Sperm Acrosomal Membrane-Associated Protein 14Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/8
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E48 or Ly-6D and Ly-6K are expressed by normal squa-
mous epithelial cells and are overexpressed in head-and-
neck squamous cell carcinoma [47,48]. Ly-6D is located
on chromosome 8q24.3 and encodes a 15 to 20 kDa GPI-
anchored protein with one cysteine rich domain [47].
The  ARS B gene encodes SLURP-1, a 9 kDa protein
[49,50]. It contains no GPI-anchor, is not glycosylated,
and is secreted. ARS B is located on chromosome 8q24.3
and mutations in ARS B are associated with Mal de
Meleda syndrome which is also know keratosis palmo-
plantaris transgrediens of Seimens. Mal de Meleda syn-
drome is a rare autosomal recessive hyperkeratotic skin
disorder involving the palms of the hand and soles of the
feet.
SLURP-2 is expressed by a number of tissues, but it is
expressed most prominently in skin and keratinocytes
[51]. It is also expressed on the cervix, esophagus, brain,
lung, stomach, small intestine, colon, rectum, uterus and
thymus. SLURP-2 is overexpressed in skin keratinocytes in
people with psoriasis vulgarsis. SLURP-2 encodes a pro-
tein predicted to have 97 amino acids and one domain
with eight conserved cysteine residues. SLURP-2 lacks a
GPI-anchor and a transmembrane domain and as a result
is secreted. It is located on chromosome 8q24.3.
Some Ly-6 genes are associated with abnormal RNA splic-
ing. A cluster of Ly-6 genes is also located in the Class III
region of the major histocompatiblity complex (MHC) on
chromosome 6p21.3. Five genes are located in this area:
LY6G6C, LY6G6D, LY6G6E, LY6G5B, and LY6G5C. The
function of these genes is not known, but they are charac-
terized by frequent transcription misssplicing [52].
Abnormal splicing of another Ly-6, gene SP-10, is also
common. Sperm-specific antigen SP-10 is expressed in the
testis. It is located on chromosome 11q23-q24. This pro-
tein differs from other Ly-6 members in that it is not GPI-
anchored. It encodes a glycosylated polypeptide of
between 18 and 34 kDa due to post-translational proteo-
lytic events and alternative splicing of RNA transcripts
[53,54].
Role of CD177 in myeloproliferation
Neutrophil CD177 mRNA levels are elevated in several
conditions associated with increased neutrophil counts.
Neutrophil CD177 mRNA levels are elevated in patients
with severe sepsis or burns, in healthy subjects given G-
CSF, and in patients with myeloproliferative disorders
[5,16,21,27,30-32]. Elevated levels of neutrophil CD177
mRNA are clearly associated with increased neutrophil
production and quantitating neutrophil CD177  mRNA
has become a useful diagnostic tool for polycythemia
vera. However, there are several other neutrophil protein
markers of increased myelopoesis that have been used to
diagnosis polycythemia vera including vitamin B12 serum
levels, leukocyte alkaline phosphatase, and lactoferrin
plasma levels [55]. It is not yet certain if CD177 mRNA
levels are more useful for diagnosing polycythemia vera
than B12, leukocyte alkaline phosphatase or lactoferrin.
The more important question concerning CD177 is what
role if any do elevated CD177 mRNA levels play in the
pathogenesis or complications of polycythemia vera?
While this question is still being investigated it is likely
that CD177 plays an important role in the pathogenesis
and clinical course of polycythemia vera. Another neu-
trophil granule protein has been found to play an impor-
tant role in myelopoiesis. The molecular defect in most
patients with severe congenital neutropenia and in all
patients with cyclic neutropenia involves a well-described
neutrophil protein that previously was not thought to be
involved with myelopoiesis, neutrophil elastase [56-58].
Neutrophil elastase is a serine protease found in neu-
trophil primary or azurophilic granules. Recently, muta-
tions in the gene encoding neutrophil elastase, ELA-2,
have been found to be associated with cyclic neutropenia
and congenital neutropenia. This suggests that CD177, an
abundant neutrophil membrane secondary granule pro-
tein could also be important in hematopoiesis.
The fact that several mouse Ly-6 genes play an important
role in proliferation, differentiation, and homing of
hematopoietic cells and lymphocytes and that several
human Ly-6 genes are overexpressed in rapidly proliferat-
ing and/or malignant cells suggests that CD177 is not just
a marker of increased neutrophil production, but it may
play an important role in the overproduction of neu-
trophils in polycythemia vera. Polycythemia vera is a
clonal disorder that may involve several molecular abnor-
malities. The abnormal expression of CD177 may not be
the initiating or the most important event, but its overex-
pression likely contributes to the pathogenesis of the
disorder.
Conclusions
Neutrophil CD177 is upregulated when myeloprolifera-
tion is increased. An elevation in neutrophil CD177
mRNA levels has become an important marker of myelo-
proliferative disorders. Further studies are needed to
determine if elevated neutrophil CD177 mRNA levels are
simply a marker of increased production of neutrophils or
if it plays a role in the pathogenisis or clinical course of
polycythemia vera.
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